Clinical Commander

Back to dossier
cardio.acute-hf.high-output-anemia.v1PRODUCTION
cardio.acute-hf.high-output-anemia.v1

Acute HF — high-output from severe anemia (Hb <7)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

High-output anemic HF — Hb <7 with HF symptoms; reduced O2 delivery → compensatory ↑ CO with vasodilation; treat anemia (transfusion judiciously to avoid TACO) + treat etiology (iron, B12, folate, hemolysis, bleed source); avoid fluid bolus + high-dose loop diuretic upfront

Inputs
1
Actions
0
Advance rule
Set
Advance when

high-output anemic HF framed

Patient inputs (10)

Iron-deficient (low ferritin, high TIBC, low TSAT), B12/folate deficient (macrocytic + hypersegs), hemolytic (high LDH, low haptoglobin, high indirect bili, high retic) — drives etiology-specific therapy

Older patients tolerate anemia poorly + higher TACO risk; transfusion threshold may be liberalized in elderly with cardiac comorbidity per FOCUS subset

Anemic patients often hypotensive due to vasodilation; orthostatic vitals reveal volume status; HR >110 at rest signals decompensation

CKD common etiology (low EPO); eGFR drives dosing of IV iron + caution with contrast if endoscopy planned; KDIGO Hb 11.5 target in CKD

GI bleed sources (NSAIDs, anticoagulants, antiplatelets, alcohol, prior peptic disease, colon cancer screening status); menstrual losses; chemotherapy/radiation; recent surgery; iron malabsorption (celiac, post-gastrectomy)

Hb (severity), MCV (etiology — micro/normo/macro), reticulocyte count (production vs destruction), peripheral smear (schistocytes for MAHA, sickle, blasts for leukemia, hypersegmented neutrophils for B12)

High CO state (CI often >4 L/min/m²) with hyperdynamic LV + dilated chambers ± functional MR/TR; rule out coexisting structural disease (AS, severe MR) that would alter management

Type 2 MI from supply-demand mismatch (NSTEMI ECG changes; troponin elevation); AFib not uncommon in elderly anemic HF; rule out STEMI requiring different pathway

Type 2 MI screen — anemia-induced supply-demand mismatch is leading cause of Type 2 MI in elderly; troponin trend differentiates demand ischemia from primary ACS

Pre-transfusion compatibility; identify alloantibodies that prolong crossmatch time (esp. multiparous + multiply transfused — sickle cell, thalassemia)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningtaco_during_transfusion_in_anemic_hf
    Transfusion-associated circulatory overload — acute dyspnea + pulmonary edema + hypoxia + JVD + new bilateral infiltrates within 6 h of transfusion in patient with HF; most common transfusion-related fatality in HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsevere_anemia_hb_below_5_with_hf_decompensation
    Hb <5 g/dL + active HF symptoms (orthopnea, pulmonary edema, hypotension) — life-threatening cardiac decompensation risk; multi-organ failure if untreated
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninghemolytic_transfusion_reaction
    Acute hemolytic reaction during/after transfusion — fever + back/flank pain + dark urine + hypotension + DIC + AKI; ABO incompatibility most common cause + fatal if not recognized
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereiron_deficient_anemia_without_obvious_source_in_adult_above_50
    New iron-deficient anemia in adult >50 without obvious source (no menstrual loss, no medication-induced) — mandatory UGI + colonoscopy to exclude GI malignancy per AGA 2020
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretype_2_mi_with_severe_anemia
    Troponin elevation + ischemic ECG changes + severe anemia (Hb <8) + ongoing chest pain — supply-demand mismatch (Type 2 MI per Universal Definition); urgent transfusion + ischemia workup
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

High-output HF from severe anemia — judicious transfusion + IV diuretic during infusion + etiology-specific repletion (FOCUS PMID 22168590; AABB 2016 PMID 26684776; AFFIRM-AHF PMID 33216035; IRONMAN PMID 36356631)
axis: high_output_anemic_hf_phenotype
Selected axis "High-output HF from severe anemia — judicious transfusion + IV diuretic during infusion + etiology-specific repletion (FOCUS PMID 22168590; AABB 2016 PMID 26684776; AFFIRM-AHF PMID 33216035; IRONMAN PMID 36356631)" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    10-20 mg IV with each unit of pRBCs (NOT high-dose upfront — anemia + over-diuresis worsens hypotension) • IV • with each transfusion + q12h prn congestion
    triggers: transfusion_in_hf, pulmonary_congestion_with_transfusion
    Mehta serial diuretic protocol Transfusion 2017 — 10-20 mg IV furosemide with each unit reduces TACO incidence; gentler than DOSE high-dose protocol because anemic patients tolerate volume loss poorly
    rxcui 4603
  • iron_sucrose
    first line
    iv_iron_replacement
    200 mg IV over 60 min weekly × 5 doses (total 1000 mg) • IV • weekly
    triggers: iron_deficient_anemia_with_chronic_hf, ckd_anemia_on_epo_with_low_tsat
    AFFIRM-AHF PMID 33216035 — IV ferric carboxymaltose in HFrEF + iron deficiency reduces hospitalization (similar effect with sucrose); preferred over PO in HF (poor PO absorption in inflammation); KDIGO recommends IV iron in dialysis patients
    rxcui 24909
  • ferric_carboxymaltose
    first line
    iv_iron_replacement
    750 mg IV × 1-2 doses (max 1500 mg over 7 d) OR weight-based: <50 kg 15 mg/kg • IV • single or 2 doses 7 d apart
    triggers: iron_deficient_anemia_with_hf_per_affirm_ahf, preferred_over_sucrose_in_outpatient_for_dose_efficiency
    AFFIRM-AHF PMID 33216035 + IRONMAN PMID 36356631 — single-dose convenience; rapid total-dose repletion; HFA-ESC 2021 Class I
    rxcui 1433693
  • ferric_derisomaltose
    add on
    iv_iron_replacement
    20 mg/kg IV (max 1000 mg) single dose • IV • single dose
    triggers: iron_deficient_anemia_in_hfref_per_ironman
    IRONMAN PMID 36356631 — large single-dose; UK + EU first-line; emerging US use
    rxcui 2274394
  • epoetin_alfa
    comorbidity specific
    erythropoiesis_stimulating_agent
    50-100 U/kg SC TIW (titrate to Hb 11-11.5 NOT >12 per CHOIR/CREATE) • SC • three times weekly
    triggers: ckd_anemia_with_egfr_below_30, chemotherapy_induced_anemia_with_chronic_use
    KDIGO 2012 — Hb target 11.5 (NOT >13 — increases mortality + thrombosis per CHOIR PMID 17108346); REQUIRES iron sufficiency (TSAT >20, ferritin >100) for response
    rxcui 105694
  • cyanocobalamin_b12
    comorbidity specific
    vitamin_replacement
    1000 µg IM daily × 7 then weekly × 4 then monthly OR 1000 µg PO daily (oral effective in non-pernicious deficiency) • IM/PO • per protocol
    triggers: b12_deficiency_with_macrocytic_anemia, pernicious_anemia_or_post_gastrectomy_or_ileal_disease
    Standard repletion; IM avoids PO absorption issues in pernicious + post-gastrectomy; recheck B12 + MMA at 3 mo
    rxcui 11248
  • folic_acid
    comorbidity specific
    vitamin_replacement
    1-5 mg PO daily × 4 mo or until repleted • PO • daily
    triggers: folate_deficiency_macrocytic_anemia, chronic_hemolysis_increased_demand_in_sickle_or_thalassemia
    Standard repletion; ALSO prophylactic in chronic hemolysis to prevent megaloblastic crisis
    rxcui 4511
  • prednisone
    comorbidity specific
    corticosteroid_glucocorticoid
    1 mg/kg/d PO (60-80 mg) tapered over weeks-months • PO • daily
    triggers: warm_autoimmune_hemolytic_anemia_aiha, evans_syndrome_with_aiha_plus_itp
    First-line for warm AIHA per BSH 2017 — taper based on Hb response; 70% respond
    rxcui 8640
  • rituximab
    add on
    monoclonal_antibody_anti_cd20
    375 mg/m² IV weekly × 4 (or 1000 mg × 2 doses 2 wk apart) • IV • weekly × 4
    triggers: refractory_warm_aiha_unresponsive_to_steroids, cold_agglutinin_disease_first_line
    Second-line warm AIHA + first-line cold agglutinin disease per BSH 2017; ~50% durable response
    rxcui 121191
  • pantoprazole
    comorbidity specific
    proton_pump_inhibitor
    40 mg IV q12h initial; 80 mg IV bolus + 8 mg/h infusion if active UGIB • IV • q12h or continuous
    triggers: gi_bleed_source_with_iron_deficient_anemia, peptic_ulcer_or_high_risk_stigmata_on_endoscopy
    ACG 2021 UGIB — high-dose IV PPI for high-risk peptic ulcer stigmata per Lau NEJM 2007
    rxcui 40790

outpatient playbook — drug actions (3)

  1. 1. maintenance PO iron alternate-day if recurrent IDA risk
    rxcui 8120
    ferrous sulfate 325 mg PO every other day • PO • every other day
    trigger: chronic IDA risk (heavy menses, GAVE, etc.)
    Stoffel JHL 2017 — alternate-day dosing improves absorption + tolerability
  2. 2. EPO maintenance for CKD
    rxcui 105694
    epoetin alfa to Hb 11.5 • SC • TIW
    trigger: CKD anemia
    KDIGO 2012
  3. 3. periodic IV iron in HFrEF + iron deficiency per AFFIRM-AHF
    rxcui 1037047
    ferric carboxymaltose 500-1000 mg IV every 4-12 mo per ferritin/TSAT trends • IV • periodic
    trigger: HFrEF + iron deficiency
    AFFIRM-AHF + IRONMAN

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Hb <7 g/dL + HF symptoms (dyspnea, orthopnea, edema, S3 gallop) → high-output anemic HF pathway; New dyspnea or orthopnea in known severe anemia (CKD on dialysis, MDS, chemotherapy, chronic GI bleed) — escalate to high-output HF workup; Anginal chest pain at rest with Hb <7 — supply-demand mismatch (Type 2 MI risk) requires urgent transfusion + ischemia workup.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — high-output from severe anemia (Hb <7)** (cardio.acute-hf.high-output-anemia.v1).
Scope: High-output anemic HF — Hb <7 with HF symptoms; reduced O2 delivery → compensatory ↑ CO with vasodilation; treat anemia (transfusion judiciously to avoid TACO) + treat etiology (iron, B12, folate, hemolysis, bleed source); avoid fluid bolus + high-dose loop diuretic upfront

No severity triggers fired against current inputs.

Plan

Regimen axis: **High-output HF from severe anemia — judicious transfusion + IV diuretic during infusion + etiology-specific repletion (FOCUS PMID 22168590; AABB 2016 PMID 26684776; AFFIRM-AHF PMID 33216035; IRONMAN PMID 36356631)**.
1. furosemide 10-20 mg IV with each unit of pRBCs (NOT high-dose upfront — anemia + over-diuresis worsens hypotension) IV with each transfusion + q12h prn congestion (loop_diuretic, first line) — Mehta serial diuretic protocol Transfusion 2017 — 10-20 mg IV furosemide with each unit reduces TACO incidence; gentler than DOSE high-dose protocol because anemic patients tolerate volume loss poorly
2. iron_sucrose 200 mg IV over 60 min weekly × 5 doses (total 1000 mg) IV weekly (iv_iron_replacement, first line) — AFFIRM-AHF PMID 33216035 — IV ferric carboxymaltose in HFrEF + iron deficiency reduces hospitalization (similar effect with sucrose); preferred over PO in HF (poor PO absorption in inflammation); KDIGO recommends IV iron in dialysis patients
3. ferric_carboxymaltose 750 mg IV × 1-2 doses (max 1500 mg over 7 d) OR weight-based: <50 kg 15 mg/kg IV single or 2 doses 7 d apart (iv_iron_replacement, first line) — AFFIRM-AHF PMID 33216035 + IRONMAN PMID 36356631 — single-dose convenience; rapid total-dose repletion; HFA-ESC 2021 Class I
4. ferric_derisomaltose 20 mg/kg IV (max 1000 mg) single dose IV single dose (iv_iron_replacement, add on) — IRONMAN PMID 36356631 — large single-dose; UK + EU first-line; emerging US use
5. epoetin_alfa 50-100 U/kg SC TIW (titrate to Hb 11-11.5 NOT >12 per CHOIR/CREATE) SC three times weekly (erythropoiesis_stimulating_agent, comorbidity specific) — KDIGO 2012 — Hb target 11.5 (NOT >13 — increases mortality + thrombosis per CHOIR PMID 17108346); REQUIRES iron sufficiency (TSAT >20, ferritin >100) for response
6. cyanocobalamin_b12 1000 µg IM daily × 7 then weekly × 4 then monthly OR 1000 µg PO daily (oral effective in non-pernicious deficiency) IM/PO per protocol (vitamin_replacement, comorbidity specific) — Standard repletion; IM avoids PO absorption issues in pernicious + post-gastrectomy; recheck B12 + MMA at 3 mo
7. folic_acid 1-5 mg PO daily × 4 mo or until repleted PO daily (vitamin_replacement, comorbidity specific) — Standard repletion; ALSO prophylactic in chronic hemolysis to prevent megaloblastic crisis
8. prednisone 1 mg/kg/d PO (60-80 mg) tapered over weeks-months PO daily (corticosteroid_glucocorticoid, comorbidity specific) — First-line for warm AIHA per BSH 2017 — taper based on Hb response; 70% respond
9. rituximab 375 mg/m² IV weekly × 4 (or 1000 mg × 2 doses 2 wk apart) IV weekly × 4 (monoclonal_antibody_anti_cd20, add on) — Second-line warm AIHA + first-line cold agglutinin disease per BSH 2017; ~50% durable response
10. pantoprazole 40 mg IV q12h initial; 80 mg IV bolus + 8 mg/h infusion if active UGIB IV q12h or continuous (proton_pump_inhibitor, comorbidity specific) — ACG 2021 UGIB — high-dose IV PPI for high-risk peptic ulcer stigmata per Lau NEJM 2007

Setting playbook (outpatient) — Long-term anemia management; surveillance for recurrence; HF surveillance if remodeling persists; etiology-specific maintenance (CKD anemia, hemoglobinopathy, MDS, AIHA on steroids)
11. maintenance PO iron alternate-day if recurrent IDA risk ferrous sulfate 325 mg PO every other day PO every other day — chronic IDA risk (heavy menses, GAVE, etc.) (Stoffel JHL 2017 — alternate-day dosing improves absorption + tolerability)
12. EPO maintenance for CKD epoetin alfa to Hb 11.5 SC TIW — CKD anemia (KDIGO 2012)
13. periodic IV iron in HFrEF + iron deficiency per AFFIRM-AHF ferric carboxymaltose 500-1000 mg IV every 4-12 mo per ferritin/TSAT trends IV periodic — HFrEF + iron deficiency (AFFIRM-AHF + IRONMAN)

Non-pharmacologic actions:
- Cancer screening completion if not done (colonoscopy at 50 or per risk)
- Menorrhagia management if reproductive-age woman with iron deficiency (gyn referral)
- Cardiac rehab maintenance if HF persisted
- Bone marrow surveillance if MDS

AVOID / contraindication checks:
- Avoid_high_dose_loop_diuretic_upfront_in_anemic_hf (worsens dehydration; use 10 20 mg IV with each unit pRBCs instead)
- Avoid_fluid_bolus_in_symptomatic_anemic_hf (worsens TACO; transfuse instead — RBCs improve oxygen carrying without volume excess)
- Transfusion_threshold_hb_7_stable_8_acute_cardiac_per_focus_aabb (do NOT exceed 9 10 in chronic anemia — no benefit + increased TACO/iron overload)
- Slow_transfusion_1_unit_over_4_hours_max_in_hf (TACO prevention)
- Single_unit_strategy_with_reassessment_between_units (TACO multiplies with each unit)
- Epo_target_hb_11.5_not_above_13 (CHOIR PMID 17108346 + CREATE — over treatment increases mortality + thrombosis)
- Iv_iron_avoid_if_active_bacterial_infection (iron is bacterial growth factor — defer until infection treated)
- Rituximab_screen_hbv_before_use (HBV reactivation risk — give entecavir prophylaxis if HBcAb+)
- Warfarin_anti_coagulation_likely_contributing_to_bleed_source (consider reversal for active GI bleed; consult hematology for AC restart timing post bleed)
- Steroids_in_aiha_check_strongyloides_serology_if_endemic (avoid reactivation hyperinfection)

Monitoring

Regimen monitoring:
- continuous spo2 ecg during transfusion plus 4h post
- vitals q15 min first hour each unit then q30 min
- daily cbc to track hb response expect 1 g per unit if no ongoing loss
- daily bmp for aki or hyperkalemia (massive transfusion can cause hyperK + hypocalcemia from citrate)
- daily exam for taco signs (new crackles, JVD, dyspnea within 6h of transfusion)
- strict io during transfusion phase
- iron studies at 4 weeks post iv iron to confirm repletion (TSAT >20, ferritin >100)
- recheck b12 mma at 3 months (homocysteine + MMA more sensitive than B12 level alone)
- cbc q3 months during steroid taper for aiha (relapse common)
- fecal occult blood or stool studies if iron deficient without obvious source

Setting (outpatient) monitoring:
- Quarterly CBC + iron
- Annual echo if EF was reduced
- Annual hematology for MDS/hemoglobinopathy
- Annual GI for established lesions

Follow-up plan: Hematology referral for ongoing etiology workup if not resolved (MDS, hemoglobinopathy, AIHA); GI referral for endoscopy completion if iron-deficient; outpatient IV iron repletion in HF clinic per AFFIRM-AHF/IRONMAN; nephrology for CKD-related anemia + EPO management; PCP + cardiology follow-up at 1-2 weeks; recheck CBC + iron studies at 4-6 weeks; counsel on warning signs (recurrent bleeding, pallor, fatigue)
- Close-out criterion: long-term plan documented + follow-up scheduled

Monitoring phase: Continuous SpO2 + ECG + BP during transfusion + 4 h post; vitals q15 min × first hour of each unit + q30 min × second hour; daily CBC to track Hb response (expect 1 g/dL rise per unit if no ongoing loss); daily BMP for AKI / hyperkalemia; daily exam for TACO (new pulmonary crackles, dyspnea, JVD); strict I/O

Disposition

Current setting: outpatient — Long-term anemia management; surveillance for recurrence; HF surveillance if remodeling persists; etiology-specific maintenance (CKD anemia, hemoglobinopathy, MDS, AIHA on steroids)

Disposition criteria:
- Long-term continuation; if etiology fully treated and no recurrence at 1 yr → discharge to PCP with annual surveillance; if chronic etiology (CKD, MDS, hemoglobinopathy) → lifelong specialist follow-up

Escalation triggers (move to higher acuity):
- Hb drop below 9 → repeat workup + transfusion threshold review
- New HF symptoms → cardiology
- New bleeding → GI or gyn
- Hemolysis flare in chronic AIHA → hematology

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Transfusion-associated circulatory overload — acute dyspnea + pulmonary edema + hypoxia + JVD + new bilateral infiltrates within 6 h of transfusion in patient with HF; most common transfusion-related fatality in HF
- [LIFE_THREATENING] Hb <5 g/dL + active HF symptoms (orthopnea, pulmonary edema, hypotension) — life-threatening cardiac decompensation risk; multi-organ failure if untreated
- [LIFE_THREATENING] Acute hemolytic reaction during/after transfusion — fever + back/flank pain + dark urine + hypotension + DIC + AKI; ABO incompatibility most common cause + fatal if not recognized

Citations

- FOCUS PMID 22168590 + AABB 2016 PMID 26684776 + 2022 ACC/AHA HF + AFFIRM-AHF (Ponikowski 2020) + KDIGO 2012 anemia in CKD [PMID:22168590](https://pubmed.ncbi.nlm.nih.gov/22168590/)
- Cited evidence (PMID 26684776) [PMID:26684776](https://pubmed.ncbi.nlm.nih.gov/26684776/)
- Cited evidence (PMID 9971864) [PMID:9971864](https://pubmed.ncbi.nlm.nih.gov/9971864/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 33216035) [PMID:33216035](https://pubmed.ncbi.nlm.nih.gov/33216035/)

Last reconciled with current guidelines: 2026-05-15.
References
  • FOCUS PMID 22168590 + AABB 2016 PMID 26684776 + 2022 ACC/AHA HF + AFFIRM-AHF (Ponikowski 2020) + KDIGO 2012 anemia in CKD — PMID:22168590
  • Cited evidence (PMID 26684776) — PMID:26684776
  • Cited evidence (PMID 9971864) — PMID:9971864
  • Cited evidence (PMID 35363499) — PMID:35363499
  • Cited evidence (PMID 33216035) — PMID:33216035